Preclinical News and Research

RSS

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade.

30 May 2022

Innovative solutions to the challenges of narcotic analysis

In this interview, Dr. Joerg Koehler and Dr. Marcio-Fernando Cobo from Bruker introduce their forensic distributed lab topology featuring the Fourier 80 CrimeLab with NMR-based narcotics profiling module.

From Bruker BioSpin Group 30 May 2022

Direct comparison of immune memory responses to four COVID-19 vaccines

Researchers evaluated host immune responses to four COVID-19 vaccines representing three different vaccine technology platforms, focusing on immune memory responses.

30 May 2022

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers evaluated a drug, atovaquone, for COVID-19 treatment.

30 May 2022

Researchers develop oil-based gels as drug delivery systems for children in resource-limited countries

Administering medications to children poses unique challenges, especially in resource-limited countries with high infant and child mortality rates.

27 May 2022

Ketamine uses a previously unknown pathway to produce an antidepressant effect, study finds

For the 280 million people suffering from depression globally, relief cannot come fast enough. Monoaminergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) take weeks to months to take effect and do not work for more than one in three patients.

26 May 2022

Study uncovers a possible mechanism that links cerebrovascular disease and Alzheimer's

For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol, or obesity have a higher likelihood of developing Alzheimer's disease.

25 May 2022

Review addresses the need for innovative adjuvant approaches and delivery strategies for the advancement of new mucosal vaccines

Researchers reviewed available mucosal vaccines discussing the current challenges and ways to advance the existing approaches.

25 May 2022

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.

24 May 2022

NIH awards first part of $30 million grant to USC team for stroke project

When administered soon after the onset of acute ischemic stroke, current approved treatments for the condition can dramatically improve patient outcomes.

24 May 2022

Montefiore Einstein Cancer Center partners with the Price Family Foundation to advance cancer equity

The National Cancer Institute-designated Montefiore Einstein Cancer Center (MECC) has partnered with the Price Family Foundation to fund eight research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.

20 May 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.

20 May 2022

Novel brain-permeable Cdk5 inhibitor alters neurobehavior in mice

James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.

20 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

New funding boost to combat antibiotic resistance

Antibiotics have saved countless lives since they were introduced in the 1940s, curing infections and making procedures like chemotherapy and surgeries safer. But their effectiveness is waning.

19 May 2022

sCPD9: a SARS-CoV-2 nasal vaccine candidate that may have superior efficacy

...

19 May 2022

Preclinical study may pave the way toward prevention and recovery of neonatal brain injuries

The findings of a new pre-clinical study published in The Journal of Neuroscience are helping pave the way toward better understanding, prevention and recovery of neonatal brain injuries.

19 May 2022

Using 'off-the-shelf' engineered stem cell based therapy for treating glioblastomas post-surgery

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most successful way to treat the disease.

19 May 2022

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

In a recent study posted to the bioRxiv* pre-print server, researchers from Belgium evaluated the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drugs in a severe combined immunodeficient (SCID) mouse model.

18 May 2022

Preclinical News and Research

First-of-its-kind platform generates antitumor immunity and improves responses to checkpoint inhibitors

Innovative solutions to the challenges of narcotic analysis

Direct comparison of immune memory responses to four COVID-19 vaccines

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers develop oil-based gels as drug delivery systems for children in resource-limited countries

Ketamine uses a previously unknown pathway to produce an antidepressant effect, study finds

Study uncovers a possible mechanism that links cerebrovascular disease and Alzheimer's

Review addresses the need for innovative adjuvant approaches and delivery strategies for the advancement of new mucosal vaccines

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

NIH awards first part of $30 million grant to USC team for stroke project

Montefiore Einstein Cancer Center partners with the Price Family Foundation to advance cancer equity

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy

Novel brain-permeable Cdk5 inhibitor alters neurobehavior in mice

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

New funding boost to combat antibiotic resistance

sCPD9: a SARS-CoV-2 nasal vaccine candidate that may have superior efficacy

Preclinical study may pave the way toward prevention and recovery of neonatal brain injuries

Using 'off-the-shelf' engineered stem cell based therapy for treating glioblastomas post-surgery

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics